Browse > Article
http://dx.doi.org/10.14776/piv.2015.22.2.75

Stenotrophomonas maltophilia and Ventilator-Associated Pneumonia in Critically Ill Pediatric Patients: a Retrospective Analysis at a Single Center  

Lee, Byung-Kee (Department of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Center)
Choi, Soo-Han (Department of Pediatrics, Hallym University Dongtan Sacred Heart Hospital)
Kim, Soo Jin (Department of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Center)
Cho, Joong Bum (Department of Critical Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center)
Ae, Hong (Department of Radiology and Center for Imaging Science, Sungkyunkwan University School of Medicine, Samsung Medical Center)
Yoo, So-young (Department of Radiology and Center for Imaging Science, Sungkyunkwan University School of Medicine, Samsung Medical Center)
Kim, Ji Hye (Department of Radiology and Center for Imaging Science, Sungkyunkwan University School of Medicine, Samsung Medical Center)
Lee, Nam Young (Department of Laboratory Medicine and Genetics, Sungkyunkwan University School of Medicine, Samsung Medical Center)
Kim, Yae-Jean (Department of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Center)
Publication Information
Pediatric Infection and Vaccine / v.22, no.2, 2015 , pp. 75-80 More about this Journal
Abstract
Purpose: Ventilator-associated pneumonia (VAP) is a serious threat in critically ill pediatric patients. Data regarding Stenotrophomonas maltophilia VAP in pediatric population is limited. We evaluated the clinical data of S. maltophilia associated VAP in critically ill pediatric patients. Methods: A retrospective chart review was performed in pediatric patients 18 years old or younger who developed S. maltophilia associated VAP at Samsung Medical Center, Seoul Korea from January 2008 to December 2012. Results: A total of 31 patients were identified S. maltophilia associated VAP. Median age was 8 months (range, 0.5 month to 16.6 years) and 13 patients were male (40.6%). Underlying illnesses were cardiologic diseases (n=11, 34.4%), hematologic oncologic malignancies (n=7, 25%), neurologic diseases (n=4, 12.5%), pulmonary diseases (n=3, 9.4%), and others (n=4, 12.5%). The median duration of ventilator use before S. maltophilia VAP diagnosis was 14 days (range, 4-256 days). Overall mortality at 30 days was 12.5% (4/32). Conclusions: S. maltophilia should be also considered as a possible pathogen for VAP in critically ill pediatric patients. Empiric antibiotic choice should include agents that are active against S. maltophilia in patients who are deteriorating on broad spectrum beta-lactam antimicrobial agents.
Keywords
Stenotrophomonas maltophilia; Pneumonia; Ventilator-Associated; Child;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Grgurich PE, Hudcova J, Lei Y, Sarwar A, Craven DE. Diagnosis of ventilator-associated pneumonia: controversies and working toward a gold standard. Curr Opin Infect Dis 2013;26:140-50.   DOI
2 Stephen WP, Alison TK, Ken K, Robert J, Louise V, Charlene G, et al. Health care-associated infections among critically ill children in the US, 2007-2012. Pediatrics 2014;134:705-12.   DOI
3 Dudeck MA, Edwards JR, Allen-Bridson K, Gross C, Malpiedi PJ, Peterson KD, et al. National healthcare safety network report, data summary for 2013, device-associated module. Am J Infect Control 2015;43:206-21.   DOI
4 Foglia E, Meier MD, Elward A. Ventilator-associated pneumonia in neonatal and pediatric intensive care unit patients. Clin Microbiol Rev 2007;20:409-25.   DOI
5 Venkatachalam V, Hendley JO, Willson DF. The diagnostic dilemma of ventilator-associated pneumonia in critically ill children. Pediatr Crit Care Med 2011;12:286-96.   DOI
6 Mariki P, Rellosa N, Wratney A, Stockwell D, Berger J, Song X, et al. Application of a modified microbiologic criterion for identifying pediatric ventilator-associated pneumonia. Am J Infect Control 2014;42:1079-83.   DOI
7 Willson DF, Conaway M, Kelly R, Hendley JO. The lack of specificity of tracheal aspirates in the diagnosis of pulmonary infection in intubated children. Pediatr Crit Care Med 2014;15:299-305.   DOI
8 Lakatos B, Jakopp B, Widmer A, Frei R, Pargger H, Elzi L, et al. Evaluation of treatment outcomes for Stenotrophomonas maltophilia bacteraemia. Infection 2014;42:553-8.   DOI
9 Ning BT, Zhang CM, Liu T, Ye S, Yang ZH, Chen ZJ. Pathogenic analysis of sputum from ventilator-associated pneumonia in a pediatric intensive care unit. Exp Ther Med 2013;5:367-71.   DOI
10 Ko HK, Yu WK, Lien TC, Wang JH, Slutsky AS, Zhang H, et al. Intensive care unit-acquired bacteremia in mechanically ventilated patients: clinical features and outcomes. PLoS One 2013;8:e83298.   DOI
11 Brooke JS. Stenotrophomonas maltophilia : an emerging global opportunistic pathogen. Clin Microbiol Rev 2012;25:2-41.   DOI
12 Araoka H, Fujii T, Izutsu K, Kimura M, Nishida A, Ishiwata K, et al. Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy. Transpl Infect Dis 2012;14:355-63.   DOI
13 Lee MR, Wang HC, Yang CY, Lin CK, Kuo HY, Ko JC, et al. Clinical characteristics and outcomes of patients with pleural infections due to Stenotrophomonas maltophilia at a medical center in Taiwan, 2004-2012. Eur J Clin Microbiol Infect Dis 2014;33:1143-8.   DOI
14 Bouza E, Granda MJ, Hortal J, Barrio JM, Cercenado E, Munoz P. Pre-emptive broad-spectrum treatment for ventilator-associated pneumonia in high-risk patients. 2013;39:1547-55.   DOI
15 Gupta S, Boville BM, Blanton Rl, Lukasiewicz G, Wincek J, Bai C, et al. A multicentered prospective analysis of diagnosis, risk factors, and outcomes associated with pediatric ventilator-associated pneumonia. Pediatr Crit Care Med 2015;16:e65-e73.   DOI
16 Centers for Disease Control and Prevention. National Healthcare Safety Network. Surveillance for ventilator-associated pneumonia (VAP). Available at http://www.cdc.gov/nhsn/PDFs/pscManual/6pscVAPcurrent.pdf [accessed on 20 Apr 2015].
17 Centers for Disease Control and Prevention. National Healthcare Safety Network. Surveillance for ventilator-associated pneumonia (VAP). Available at http://www.cdc.gov/nhsn/acute-care-hospital/vap/index.html [accessed on 20 Apr 2015].
18 Casado RJ, de Mello MJ, de Aragão RC, de Albuquerque MF, Correia JB. Incidence and risk factors for health careassociated pneumonia in a pediatric intensive care unit. Crit Care Med 2011;39:1968-73.   DOI
19 Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT, et al. Attributable mortality of ventilatorassociated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. The Lancet Infectious Diseases 2013;13:665-71.   DOI
20 Brooke JS. New strategies against Stenotrophomonas maltophilia : a serious worldwide intrinsically drug-resistant opportunistic pathogen. Anti Infect Ther 2014;12:1-4.   DOI